

81. (New) A method for administering an extendin or an extendin agonist to a subject in need thereof, comprising nasally administering at least about 3.5 µg per day of said extendin or extendin agonist to said subject in single or divided doses.

82. (New) A method for administering an extendin or an extendin agonist to a subject in need thereof, comprising the buccal administration of at least about 3.5 µg per day of said extendin or extendin agonist to said subject in single or divided doses.

83. (New) A method for administering an extendin or an extendin agonist to a subject in need thereof, comprising the sublingual administration of at least about 3.5 µg per day of said extendin or extendin agonist to said subject in single or divided doses.

REMARKS

The new claims and amendments introduced herewith are not responsive to any action on the merits in this case, as no action on the merits has yet been issued or received. Nor do the amendments provided herewith constitute new matter. Thenewly added claims and amendments have specification support, for example, on pages 17-18 of the application as originally filed. The specification changes of "i.e." to "e.g." on page 17 bridging 18 merely correct typographical errors and the changes are consistent with the immediate preceding paragraph on page 17 that recites .005 ug/kg/dose for parenteral administrations and the statement on lines 25-26 of page 17 that oral doses "will include from about 50 to about 100 times" this amount.

Pursuant to new Rule 1.121, a separate sheet bearing the introduced changes to the specification is provided herewith.

The Commissioner is authorized to charge any additional fee required or to credit any overpayment to our Deposit Account No. 50-1273.

Respectfully submitted,

BROBECK, PHLEGER & HARRISON LLP

Dated: 7/13/01

By: 

Edward O. Kreusser
Reg. No. 38,523

EOK:jxb

BROBECK, PHLEGER & HARRISON LLP
12390 El Camino Real
San Diego, CA 92130-2081
Telephone: (858) 720-2500
Facsimile: (858) 720-2555